Loading...
  • progression
  • First, the detection of different oxygenation levels in gliomas of different WHO grade may be very valuable in the investigation of processes leading to the malignant progression of these tumors. (aacrjournals.org)
  • clinical trials
  • Recent advances in Platinum (IV) anticancer agents that have been in clinical trials and photoactivatable Platinum (IV) complexes are also summarized, and the purpose here is to provide insight into the requirements for the antitumor activity of Platinum (IV) complexes and a basis for progressing in a new platinum compound. (scirp.org)
  • Proteasome inhibitors such as PS-341, a dipeptide boronic acid analogue, represent an interesting new class of potential anticancer drugs, which are entering early-phase clinical trials. (aacrjournals.org)
  • This is supported by preclinical data as well as results from early clinical trials using the selective proteasome inhibitor bortezomib (Velcade, formerly known as PS341), which is currently the only proteasome inhibitor tested for anticancer effects in humans ( 3 ). (aacrjournals.org)
  • It is now recognized that clinical trials of novel agents should include biological markers to determine the drug effects at the molecular level in addition to standard clinical response end points. (aacrjournals.org)
  • cancer
  • Professor Rockwell taught radiation biology, pharmacology, cancer biology, ethics, and career development skills in several Yale courses and lecture series. (yale.edu)
  • Knowledge of the kinetics and property of Pt (IV) compounds has promoted the development of potent platinum-based antitumor drugs with suitable properties for oral administration and antitumor activity in cisplatin-resistant human cancer cells. (scirp.org)
  • It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. (hindawi.com)
  • The clinically acquired resistance can be caused by decreased drug accumulation which includes reduced uptake or increased efflux of cisplatin, increased drug detoxification by cellular thiols, increased DNA repair or tolerance of cisplatin-damaged DNA and the ability of the cancer cells to evade cisplatin-induced cell death. (hindawi.com)
  • As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types. (drugbank.ca)
  • In the Feb. 19 issue of Nature , researchers from Massachusetts General Hospital (MGH) describe how proliferating cancer cells compress both blood and lymphatic vessels within tumors. (bio-medicine.org)
  • The MGH team investigated whether solid pressure exerted by proliferating cancer cells could compromise blood supply in the same way that stepping on a hose cuts off the flow of water. (bio-medicine.org)
  • Hypoxic tumor regions also impede immune responses, and may promote the growth of cancer stem cells ( 5 , 6 ). (aacrjournals.org)
  • As human cancer remains a cause of high morbidity and mortality worldwide, an urgent need of new, selective, and more efficient drugs is evident. (frontiersin.org)
  • The drugs enter the bloodstream and circulate the body, attacking cancer cells by preventing them from multiplying. (roswellpark.org)
  • The findings showed that SAG E3 ubiquitin ligase plays an essential role in cancer cell proliferation and tumor growth and may serve as a promising anticancer and radiosensitizing target. (aacrjournals.org)
  • and ( c ) SAG siRNA silencing selectively sensitizes radioresistant cancer cells to radiation. (aacrjournals.org)
  • Loss of SKIP sensitizes cancer cells to the apoptotic effects of DNA damage-inducing anticancer drugs. (healthcanal.com)
  • However, there is little direct evidence to show that suppression of NF-κB activation occurs in cancer patients treated with bortezomib, and it is important to consider other potential molecular mechanisms of anticancer effect. (aacrjournals.org)
  • Specifically targeting these molecular motors in cancer cells would then prevent the cancer cells from growing into a larger tumor, said Dekker. (bio-medicine.org)
  • glioblastoma
  • An additional study is evaluating oral BAL101553 in combination with standard radiation in patients with newly-diagnosed glioblastoma. (pipelinereview.com)
  • 4, 5, 6 BAL101553 efficiently distributes to the brain, with anticancer activity in glioblastoma models. (pipelinereview.com)
  • Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. (bioportfolio.com)
  • Such an association would be a novel finding as, to my knowledge, a prognostic role of tumor oxygenation in glioblastoma detected by either needle electrode or endogenous or injectable marker has not yet been documented. (aacrjournals.org)
  • survival
  • In human cancers, multiple components of this system become dysregulated and provide growth and survival advantages to tumor cells ( 2 ). (aacrjournals.org)
  • SAG mRNA was overexpressed in human lung tumor tissues with a correlation to poor patient survival. (aacrjournals.org)
  • To investigate whether SAG serves as an anticancer target, we determined the effect of SAG silencing on cell proliferation, survival, and radiosensitivity. (aacrjournals.org)
  • malignancies
  • Because the IGF-I pathway is active in the majority of solid and hematologic malignancies, targeting this system has been an area of increasing drug development interest. (aacrjournals.org)
  • As detailed studies on ACPs mechanisms of action are crucial for optimizing drug development, in this review we provide an overview of the literature concerning peptides' structure, modes of action, selectivity, and efficacy and also summarize some of the many ACPs studied and/or developed for targeting different solid and hematologic malignancies with special emphasis on the first group. (frontiersin.org)
  • Conclusions The effects of Laromustine on solid tumors and with radiation are complex and are influenced by microenvironmental and proliferative heterogeneity within these malignancies. (cylch.org)
  • 2005) that provide little insight into the potential efficacy of this agent for solid malignancies. (cylch.org)
  • hematologic
  • Bortezomib (Velcade, formerly PS-341) represents the first Food and Drug Administration-approved proteasome inhibitor to treat multiple myeloma and hematologic as well as solid tumors ( 2 ). (aacrjournals.org)
  • regimens
  • growth assays showed effects of regimens combining Laromustine and radiation that were compatible with additive or subadditive interactions. (cylch.org)
  • proliferation
  • In addition, we compared the effects of Laromustine on proliferating and quiescent cells, because solid tumors generally contain large numbers of non-proliferating clonogenic cells, which are resistant to the many anticancer drugs that target pathways critical to cell proliferation. (cylch.org)
  • Proteasome
  • The fast-track approval of bortezomib has spurred a great wave of interest in the development of anticancer reagents against the ubiquitin-proteasome system. (aacrjournals.org)
  • response
  • Tumor response will be summarized, and the 95% confidence interval for ORR (complete response [CR] + partial response [PR]) will be presented. (clinicaltrials.gov)
  • We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin-induced apoptosis by protein kinases. (hindawi.com)
  • Furthermore, there are data to recommend that variability in the response of specific AML individuals to Laromustine may be related to variations in the levels of AGT in the tumors (Giles 2007). (cylch.org)
  • toxicity
  • Strategies described for drug development and for increasing peptide selectivity toward specific cells while reducing toxicity are also discussed. (frontiersin.org)